Sanofi Company Profile (NYSE:SNY)

About Sanofi

Sanofi logoSanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company's principal activities. Under the Company's Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: SNY
  • CUSIP:
Key Metrics:
  • Previous Close: $37.83
  • 50 Day Moving Average: $39.00
  • 200 Day Moving Average: $40.52
  • 52-Week Range: $37.41 - $51.88
  • Trailing P/E Ratio: 21.19
  • Foreward P/E Ratio: 12.95
  • P/E Growth: 1.88
  • Market Cap: $98.30B
  • Outstanding Shares: 2,574,011,000
  • Beta: 1.01
Profitability:
  • Net Margins: 11.89%
  • Return on Equity: 25.34%
  • Return on Assets: 14.15%
Debt:
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.00%
Additional Links:
Companies Related to Sanofi:

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $65.33 (71.07% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016Leerink SwannReiterated RatingBuyView Rating Details
9/23/2016Piper Jaffray Cos.Initiated CoverageNeutralView Rating Details
9/15/2016JPMorgan Chase & Co.Reiterated RatingUnderweightView Rating Details
9/14/2016Jefferies GroupReiterated RatingHoldView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralView Rating Details
9/8/2016Berenberg BankUpgradeHold -> BuyView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/12/2016Barclays PLCUpgradeEqual Weight -> OverweightView Rating Details
5/3/2016HSBCDowngradeBuy -> HoldView Rating Details
5/3/2016Bank of America Corp.Reiterated RatingBuy$58.00View Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyView Rating Details
3/18/2016Goldman Sachs Group Inc.Reiterated RatingNeutralView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00View Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceView Rating Details
12/1/2015Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyView Rating Details
7/13/2015Deutsche Bank AGUpgradeBuyView Rating Details
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details
1/23/2015Kepler Capital MarketsDowngradeHoldView Rating Details
10/15/2014Credit Suisse Group AGUpgradeNeutral -> OutperformView Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Sanofi (NYSE:SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/29/2015Q315$0.88$0.89ViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73ViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79ViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72ViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81ViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sanofi (NYSE:SNY)
Current Year EPS Consensus Estimate: $3.03 EPS
Next Year EPS Consensus Estimate: $2.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.65$0.72$0.69
Q2 20162$0.72$0.75$0.74
Q3 20161$0.90$0.90$0.90
Q4 20161$0.65$0.65$0.65
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Sanofi (NYSE:SNY)
Annual Dividend:$1.12
Dividend Yield:2.93%
Dividend Growth:-1.60% (3 Year Average)
Payout Ratio:61.88% (Based on Trailing 12 Months of Earnings)
36.96% (Based on Current Year Consensus EPS Estimate)
37.97% (Based on Next Year Consensus EPS Estimate)

Dividend History for Sanofi (NYSE:SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sanofi (NYSE:SNY)
DateHeadline
News IconRegeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Jou... (NYSE:SNY)
ih.advfn.com - October 1 at 6:13 AM
publicnow.com logoSanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine​ (NYSE:SNY)
www.publicnow.com - October 1 at 6:13 AM
feeds.reuters.com logoRegeneron eczema drug reduces itch and anxiety, two studies show (NYSE:SNY)
feeds.reuters.com - October 1 at 2:19 AM
marketrealist.com logoDiabetes Care Market Is Expected to See Fast Growth (NYSE:SNY)
marketrealist.com - September 30 at 7:30 PM
News IconDeaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Stock Tanks (NYSE:SNY)
www.pharmalive.com - September 30 at 1:28 PM
seekingalpha.com logoSanofi announces thematic call on Dupilumab (NYSE:SNY)
seekingalpha.com - September 30 at 1:28 PM
marketrealist.com logoRegeneron Is a Late Entrant in Immuno-Oncology Space (NYSE:SNY)
marketrealist.com - September 29 at 12:48 PM
publicnow.com logoUnderstanding diabetes in the developing world (NYSE:SNY)
www.publicnow.com - September 29 at 12:48 PM
streetinsider.com logoRegeneron (REGN), Sanofi (SNY) Announce Dupilumab BLA Accepted for Priority Review by FDA - StreetInsider.com (NYSE:SNY)
www.streetinsider.com - September 28 at 12:39 PM
streetinsider.com logoSanofi (SNY) Receives $43.2M BARDA Grant for Zika Vaccine Development - StreetInsider.com (NYSE:SNY)
www.streetinsider.com - September 28 at 12:39 PM
capitalcube.com logoETF’s with exposure to Sanofi : September 27, 2016 (NYSE:SNY)
www.capitalcube.com - September 27 at 7:19 PM
News IconTop Gainers of the Day: Sanofi (NYSE:SNY) from Drug Manufacturers – Major (NYSE:SNY)
twincountynews.com - September 27 at 11:59 AM
wsj.com logoCorporate-Bond Buying Attracts Doubts as Growth Tool for Europe (NYSE:SNY)
www.wsj.com - September 26 at 7:25 PM
streetinsider.com logoSanofi (SNY) Receives $43.2M BARDA Grant for Zika Vaccine Development (NYSE:SNY)
www.streetinsider.com - September 26 at 7:25 PM
feeds.reuters.com logoSanofi gets $43 mln U.S. funding to spur Zika vaccine development (NYSE:SNY)
feeds.reuters.com - September 26 at 12:18 PM
seekingalpha.com logoFDA accepts dupilumab BLA for review; action date March 29, 2017 (NYSE:SNY)
seekingalpha.com - September 26 at 10:20 AM
rttnews.com logoRegeneron, Sanofi: FDA Accepts Dupilumab BLA For Priority Review - Quick Facts (NYSE:SNY)
www.rttnews.com - September 26 at 10:20 AM
thecountrycaller.com logoThis Might Be Sanofi SA's (ADR) (SNY) Biggest Win In 2017 (NYSE:SNY)
www.thecountrycaller.com - September 26 at 10:20 AM
News IconRegeneron, Sanofi get priority review, March 29 PDUFA date for atopic dermatitis drug (NYSE:SNY)
www.fiercebiotech.com - September 26 at 10:20 AM
feeds.reuters.com logoSanofi may win U.S. approval of $3 bln eczema drug by March (NYSE:SNY)
feeds.reuters.com - September 26 at 3:39 AM
feeds.reuters.com logoBRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA (NYSE:SNY)
feeds.reuters.com - September 26 at 1:59 AM
fidaily.com logoPiperJaffray Begins Coverage on Sanofi American Depositary Shar (SNY) By Announcing An Initial Rating Of “Neutral” (NYSE:SNY)
www.fidaily.com - September 24 at 11:46 AM
News IconDrug Manufacturers – Major: Sanofi (NYSE:SNY) Position of the day (NYSE:SNY)
twincountynews.com - September 24 at 11:46 AM
finance.yahoo.com logoCoverage initiated on Sanofi by Piper Jaffray (NYSE:SNY)
finance.yahoo.com - September 23 at 6:49 PM
thestreet.com logoNew Setback for Sanofi's Lantus Increases Need for M&A - TheStreet.com (NYSE:SNY)
www.thestreet.com - September 22 at 7:02 PM
News IconThe Key Numbers To Watch From Sanofi (NYSE:SNY)'s Earnings - The Voice Registrar (NYSE:SNY)
voiceregistrar.com - September 22 at 7:02 PM
News IconCitigroup Inc. Reaffirms Neutral Rating for Sanofi SA (SNY) - Petro Global News 24 (NYSE:SNY)
petroglobalnews24.com - September 22 at 12:12 PM
News IconA look at a High Market Cap Stock: Sanofi, SNY – The Daily Leicester - The Daily Leicester (NYSE:SNY)
thedailyleicester.com - September 22 at 12:12 PM
feeds.reuters.com logoUPDATE 1-UnitedHealth trims drug coverage, including Sanofi insulin (NYSE:SNY)
feeds.reuters.com - September 22 at 7:18 AM
mysmartrend.com logoSanofi-Aventis Set to Possibly Rebound After Yesterday's Selloff of 2.57% (NYSE:SNY)
www.mysmartrend.com - September 21 at 6:56 PM
gurufocus.com logoWells Fargo One of Only Two Buffett Stocks at 52-Week Low Price After Scandal (NYSE:SNY)
www.gurufocus.com - September 21 at 6:56 PM
forbes.com logoCone Snail Venom Could Inspire Fast-Acting Insulin For Diabetes (NYSE:SNY)
www.forbes.com - September 21 at 6:56 PM
News IconSanofi lawsuit tries to hold Merck Lantus biosimilar at bay (NYSE:SNY)
www.fiercepharma.com - September 21 at 11:31 AM
News IconLeading stocks in today’s market: Sanofi (NYSE:SNY) (NYSE:SNY)
twincountynews.com - September 21 at 11:31 AM
seekingalpha.com logoSanofi files suit against Merck over patents (NYSE:SNY)
seekingalpha.com - September 20 at 11:43 AM
cnn.com logoMeet Big Pharma's new female CEO (NYSE:SNY)
money.cnn.com - September 20 at 11:43 AM
News IconIs Sanofi (NYSE:SNY), a large market cap stock a smart buy? (NYSE:SNY)
twincountynews.com - September 20 at 11:43 AM
News IconFrontline Trades in Focus- Raytheon (NYSE:RTN), Sanofi (NYSE ... - Seneca Globe (NYSE:SNY)
www.senecaglobe.com - September 19 at 7:19 PM
investorplace.com logoSanofi SA (ADR) (SNY) Sues Merck & Co., Inc. (MRK) Over Multiple Patent Infringements - Investorplace.com (NYSE:SNY)
investorplace.com - September 19 at 7:19 PM
investorplace.com logoSanofi SA (ADR) (SNY) Sues Merck & Co., Inc. (MRK) Over Multiple Patent Infringements (NYSE:SNY)
investorplace.com - September 19 at 12:21 PM
seekingalpha.com logoSanofi files suit against Merck over patents - Seeking Alpha (NYSE:SNY)
seekingalpha.com - September 19 at 11:55 AM
streetinsider.com logoSanofi (SNY) Announces Positive Data from Lemtrada Extension Study in RRMS (NYSE:SNY)
www.streetinsider.com - September 17 at 6:51 PM
News IconSanofi's (SNY): Stock to Watch - Hot Stocks Point (NYSE:SNY)
www.hotstockspoint.com - September 16 at 7:06 PM
streetinsider.com logoSanofi (SNY) Announces Positive Data from Lemtrada Extension ... - StreetInsider.com (NYSE:SNY)
www.streetinsider.com - September 16 at 7:06 PM
finance.yahoo.com logo10:32 am Sanofi announces 'positive' new six-year investigational data from the extension study of Lemtrada in patients with relapsing remitting multiple sclerosis (NYSE:SNY)
finance.yahoo.com - September 16 at 7:06 PM
publicnow.com logoTreatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials ​ (NYSE:SNY)
www.publicnow.com - September 16 at 7:06 PM
mysmartrend.com logoAnalyst Rating Flashback: Sanofi-Aventis Down 2.9% Since Upgraded 7 Days Ago (SNY) (NYSE:SNY)
www.mysmartrend.com - September 16 at 10:56 AM
rttnews.com logoSanofi Announces Positive Data From Study Of Lemtrada In Patients With RRMS (NYSE:SNY)
www.rttnews.com - September 16 at 10:56 AM
News IconTreatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzy... (NYSE:SNY)
ih.advfn.com - September 16 at 10:56 AM
finance.yahoo.com logoSanofi (SNY) Presents Positive Diabetes Data on iGlarLixi - Yahoo Finance (NYSE:SNY)
finance.yahoo.com - September 15 at 7:28 PM

Social

Sanofi (NYSE:SNY) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff